STAT+: Congress extends some pandemic preparedness programs, but not all
WASHINGTON — Congress temporarily extended a few pandemic-preparedness programs when it forestalled a government shutdown…
Category: STAT+
STAT+: Verily lands $38 million deal with CDC for wastewater surveillance
Alphabet’s life sciences company Verily has scored its first Centers for Disease Control contract, a…
STAT+: Court strikes down Trump-era rule that allowed health insurers to broadly use copay accumulators
A U.S. judge has struck down a Trump administration rule that allowed health insurers not…
STAT+: Former FDA official lays out how to keep patients safe from risky medical devices
Madris Kinard’s unlikely journey to becoming a champion for patient safety started in a fire…
STAT+: Pharmalittle: Court allows Medicare drug price negotiation to proceed; J&J will not enforce patents on key TB drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Syndax’s leukemia drug succeeds in pivotal study
Syndax Pharmaceuticals’ treatment for a genetically defined form of advanced leukemia met its goal in…
STAT+: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder
Mirum Pharmaceuticals reported on Monday that a drug it recently acquired to treat cerebrotendinous xanthomatosis,…
STAT+: The biotech scorecard for the fourth quarter: 16 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth…
STAT+: What we owe ALS patients — and why one company fell short
What do you say to a patient when the FDA rejects “their” experimental drug —…
STAT+: Obama-era Medicare innovation initiative doesn’t save money after all
WASHINGTON — A key Obama-era initiative was supposed to save Medicare money by testing new…
STAT+: More hospital and outpatient visits expected to persist through fall and winter
Health care providers and health insurance companies are closing the books on their third quarters,…
STAT+: New lawsuit highlights another wrinkle for settling disputes over surprise medical bills
After Congress officially outlawed surprise medical bills last year, there’s been endless, litigious debate as…
STAT+: FDA seeks to regulate lab-developed tests, closing the ‘Theranos loophole’
The Food and Drug Administration on Friday announced its intention to start regulating tests developed…
STAT+: Unitaid slams J&J over pricing and patents for a tuberculosis drug
In a highly unusual move, Unitaid has publicly criticized Johnson & Johnson over its pricing…
STAT+: Generic makers fall short when providing access to low- and middle-income countries, analysis finds
A handful of the largest purveyors of generic medicines have made only halting progress to…
STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling
In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies…
STAT+: Brigham and Women’s exec opens up about the Dana-Farber Cancer Institute split, and what it means for the future of cancer care
The severing of ties between two of Boston’s biggest health care giants has placed one…
STAT+: GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours
WASHINGTON — The top ranking Republican on the Senate health committee is launching an investigation…
STAT+: Pharmalittle: FDA advisers vote overwhelmingly against ALS treatment; weight-loss drugs scrutinized over reports of suicidal thoughts
Top of the morning to you, and a fine one it is. Despite overcast skies,…
STAT+: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments
The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the…
STAT+: 6 ways the government could help address drug shortages, including in cancer
WASHINGTON — Republicans and Democrats alike want to stop drug shortages from happening. The vexing…
STAT+: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm
A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a…
STAT+: U.S. government’s next-gen Covid effort gives small biotech up to $433 million
The U.S. government’s “Project Nextgen,” its effort to accelerate and streamline the rapid development of…
STAT+: Biogen shutters digital health group, nixes Apple study, as part of cost cuts
Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person…
STAT+: Senate committee chair tries to spark negotiations to keep Medicare solvent
WASHINGTON — The Senate Budget Committee started what could become a bipartisan effort to extend…
STAT+: Pharmalittle: Pharma would lose loyal ally if Menendez leaves Senate; EMA to discuss anesthesia risk for weight-loss drugs
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Over-the-counter Sudafed doesn’t work. Neither does our system for evaluating older drugs
You would have been forgiven for being surprised on Sept. 12 when a panel of…
STAT+: The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the story
On a mild May day in 1993, about 60 scientists and doctors gathered on a…
STAT+: Bubble bursts: 2021 health tech IPOs and SPACs lose value, burn cash
In less than two years, digital health’s high-flying class of public debuts have landed with…
STAT+: ARPA-H finally settles on its headquarters: hubs in Boston, Texas, and D.C.
WASHINGTON — Cities and states have been clamoring to play host to the Advanced Research…
STAT+: Just how much money do drugmakers gain from patent extensions?
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so…
STAT+: With Menendez indictment, pharmaceutical industry could lose a key ally
WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry…
STAT+: Pharmalittle: FDA to furlough one-fifth of staff if government shuts down; FDA cites ‘grossly deficient’ data for ALS drug
Hello, everyone, and nice to see you again after we engaged in an extended respite….
STAT+: Intercept, once a biotech trailblazer, sells itself for less than $1 billion
Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the…
STAT+: Early data are promising for autoimmune disease drug from Roivant Sciences’s Immunovant
Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’s…
.jpg)
STAT+: Ionis inches toward first solo drug launch with late-stage trial success for rare genetic disease therapy
Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on…
STAT+: Medicare Advantage plans for dual-eligible enrollees set to get Senate scrutiny
The Senate has set its eyes on regulating insurance plans for some of the most…
Opinion: STAT+: The problem with potential changes to the biosimilar regulatory framework
Biosimilars are no longer a new and untested class of medicines. Today, they provide critical…
STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, writing to…
.jpg)
STAT+: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds
The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an…
STAT+: What ever happened to biotech’s big comeback?
This was supposed to be the year of the biotech comeback, when promising new medicines…
STAT+: Cancer drug shortages widen disparities between big systems and small
For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies…
STAT+: CommonSpirit’s answer to losing money: get bigger
CommonSpirit Health keeps adding more hospitals — and billions in new debt — even as…
STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial
LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain…
STAT+: FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia
An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant…
STAT+: Four burning questions about the potential 85,000-worker Kaiser Permanente strike
This week, the Coalition of Kaiser Permanente Unions is negotiating a new national contract with…
STAT+: Bernie Sanders, Bill Cassidy clash over proposal to increase primary care doctors, nurses
WASHINGTON — In a striking display of discord Thursday, leaders of the Senate’s health committee…
STAT+: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny
Hello, everyone, and how are you this fine, sunny morning? We are doing just fine,…